Business Context and Reporting Period
This Form 6-K filing by Sanofi, a foreign private issuer, covers the month of May 2017. The report serves to incorporate by reference two press releases issued during this period regarding regulatory milestones for specific pharmaceutical products.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update on product approvals rather than a financial statement.
Material Changes and Regulatory Developments
- Insulin Lispro Biosimilar: On May 19, 2017, Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for the approval of Sanofi's insulin lispro biosimilar.
- Kevzara (sarilumab): On May 22, 2017, Sanofi and Regeneron announced that the U.S. Food and Drug Administration (FDA) approved Kevzara for the treatment of moderately to severely active rheumatoid arthritis in adult patients.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies. The content is limited to the announcement of the two regulatory approvals listed above.
Investor Verification Checklist
- Verify the commercial launch timeline for the insulin lispro biosimilar following the CHMP recommendation.
- Confirm the market access and reimbursement status for Kevzara in the U.S. following FDA approval.
- Review the full text of the press releases (Exhibits 99.1 and 99.2) for specific details on the scope of the approvals.